Endometrial Cancer Clinical Trial
Official title:
A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer
RATIONALE: Lymphadenectomy may remove cancer cells that have spread to nearby lymph nodes.
Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether
conventional surgery is more effective with or without lymphadenectomy and/or radiation
therapy in treating endometrial cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of conventional surgery
with or without lymphadenectomy and/or radiation therapy in treating patients who have
endometrial cancer.
OBJECTIVES:
- Compare the effects of conventional surgery alone and conventional surgery plus
lymphadenectomy in patients with endometrial cancer preoperatively thought to be
confined to the uterine corpus.
- Determine the effect of postoperative adjuvant external beam radiotherapy on quality of
life and survival of a subset of these patients at high risk of relapse and with no
macroscopic disease after surgery.
OUTLINE: This is a randomized, multicenter study. Patients are randomized in both the
surgery and radiotherapy segments of the study.
- Surgery: Patients are randomized to 1 of 2 surgery arms.
- Arm I: Patients undergo conventional surgery (total abdominal hysterectomy and
bilateral salpingo-oophorectomy).
- Arm II: Patients undergo conventional surgery as in arm I followed by
lymphadenectomy with systematic dissection of the iliac and obturator nodes.
- Radiotherapy: Patients at high risk of relapse who have no postoperative macroscopic
disease are randomized to 1 of 2 radiotherapy arms. (Patients may enter the
radiotherapy randomization after surgery off study.)
- Arm I: Patients receive in 20-25 fractions of external beam radiotherapy (total
dose of 40-46 Gy) over 4-5 weeks.
- Arm II: Patients receive no external beam radiotherapy. NOTE: Some patients
receive vault brachytherapy regardless of radiotherapy randomization.
Quality of life is assessed before therapy and at 2 and 5 years after therapy.
Patients are followed every 3 months for 1 year and then every 6 months for 1 year.
PROJECTED ACCRUAL: A minimum of 1400 patients will be accrued for the surgical component of
this study and at least 900 patients (including additional patients not participating in the
surgical component of this study) will be accrued for the radiotherapy component of this
study.
;
Allocation: Randomized, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02413606 -
ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?
|
N/A |